MYOF

Across TCGA pan-cancer cohorts, MYOF mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MYOF data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MYOF mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MYOF expression acts as an unfavorable survival marker.

CCRCC, PDAC, and LUAD are the cancer types where MYOF mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	All	0.615	0.927	<.001	38	view →
PDAC	DFS	Quartile	II,III,IV	0.273	0.702	<.001	31	view →
LUAD	DFS	Median	II,III,IV	0.231	0.771	.004	14	view →
LSCC	OS	Tertile	All	0.819	0.998	.013	6	view →
GBM	OS	Quartile	All	0.770	0.925	.010	5	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MYOF–CCRCC (OS)

Open the CCRCC breakdown →